Overview

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Status:
RECRUITING

Trial end date:
2027-09-30

Target enrollment:

Participant gender:

Summary

To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Carboplatin
Cyclophosphamide
Doxorubicin
Paclitaxel
pembrolizumab
Taxes